Praxis Precision Medicines (PRAX) Competitors $50.98 -3.40 (-6.25%) Closing price 04:00 PM EasternExtended Trading$50.98 0.00 (0.00%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRAX vs. KYMR, MTSR, MLTX, LNTH, TLX, CRNX, AMRX, CNTA, NAMS, and HCMShould you be buying Praxis Precision Medicines stock or one of its competitors? The main competitors of Praxis Precision Medicines include Kymera Therapeutics (KYMR), Metsera (MTSR), MoonLake Immunotherapeutics (MLTX), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Crinetics Pharmaceuticals (CRNX), Amneal Pharmaceuticals (AMRX), Centessa Pharmaceuticals (CNTA), NewAmsterdam Pharma (NAMS), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Praxis Precision Medicines vs. Its Competitors Kymera Therapeutics Metsera MoonLake Immunotherapeutics Lantheus Telix Pharmaceuticals Crinetics Pharmaceuticals Amneal Pharmaceuticals Centessa Pharmaceuticals NewAmsterdam Pharma HUTCHMED Kymera Therapeutics (NASDAQ:KYMR) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations. Which has more risk & volatility, KYMR or PRAX? Kymera Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. Comparatively, Praxis Precision Medicines has a beta of 2.62, meaning that its stock price is 162% more volatile than the S&P 500. Do institutionals & insiders hold more shares of KYMR or PRAX? 67.8% of Praxis Precision Medicines shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 2.7% of Praxis Precision Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is KYMR or PRAX more profitable? Praxis Precision Medicines has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -616.03%. Kymera Therapeutics' return on equity of -31.60% beat Praxis Precision Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-616.03% -31.60% -27.12% Praxis Precision Medicines N/A -60.07%-54.84% Which has higher valuation and earnings, KYMR or PRAX? Praxis Precision Medicines has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Praxis Precision Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M87.42-$223.86M-$3.47-16.59Praxis Precision Medicines$8.55M125.51-$182.82M-$12.29-4.15 Does the media favor KYMR or PRAX? In the previous week, Kymera Therapeutics had 8 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 11 mentions for Kymera Therapeutics and 3 mentions for Praxis Precision Medicines. Kymera Therapeutics' average media sentiment score of 0.48 beat Praxis Precision Medicines' score of 0.34 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Praxis Precision Medicines 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend KYMR or PRAX? Kymera Therapeutics currently has a consensus target price of $61.26, suggesting a potential upside of 6.45%. Praxis Precision Medicines has a consensus target price of $85.56, suggesting a potential upside of 67.82%. Given Praxis Precision Medicines' higher possible upside, analysts clearly believe Praxis Precision Medicines is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.95Praxis Precision Medicines 2 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.75 SummaryKymera Therapeutics beats Praxis Precision Medicines on 10 of the 17 factors compared between the two stocks. Get Praxis Precision Medicines News Delivered to You Automatically Sign up to receive the latest news and ratings for PRAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRAX vs. The Competition Export to ExcelMetricPraxis Precision MedicinesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.14B$3.36B$6.16B$10.57BDividend YieldN/A2.28%5.66%4.69%P/E Ratio-4.1522.0285.5827.12Price / Sales125.51463.22612.62135.31Price / CashN/A46.3226.3031.10Price / Book2.139.9612.876.67Net Income-$182.82M-$52.42M$3.30B$276.23M7 Day Performance-2.67%5.95%4.80%3.31%1 Month Performance8.82%11.59%8.11%10.76%1 Year Performance-21.50%25.01%75.85%33.58% Praxis Precision Medicines Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRAXPraxis Precision Medicines2.2552 of 5 stars$50.98-6.3%$85.56+67.8%-16.3%$1.14B$8.55M-4.15110KYMRKymera Therapeutics1.9895 of 5 stars$51.00+3.8%$59.95+17.6%+34.5%$3.51B$47.07M-14.70170MTSRMetseraN/A$53.58+60.8%$63.50+18.5%N/A$3.50BN/A0.0081High Trading VolumeMLTXMoonLake Immunotherapeutics2.9769 of 5 stars$54.98+2.2%$74.43+35.4%-84.8%$3.45BN/A-19.782Analyst RevisionGap UpLNTHLantheus4.6777 of 5 stars$50.11-0.6%$85.50+70.6%-50.1%$3.43B$1.53B13.33700TLXTelix Pharmaceuticals4.3454 of 5 stars$10.05+0.7%$21.50+113.9%N/A$3.38B$516.72M0.00N/AShort Interest ↓CRNXCrinetics Pharmaceuticals3.9147 of 5 stars$33.72-0.6%$65.33+93.8%-23.1%$3.19B$1.04M-8.20210Insider TradeAMRXAmneal Pharmaceuticals2.5061 of 5 stars$10.00+1.9%$12.00+20.0%+20.1%$3.08B$2.79B1,001.008,100CNTACentessa Pharmaceuticals3.3586 of 5 stars$23.38+2.6%$32.38+38.5%+45.7%$3.05B$6.85M-13.06200Analyst ForecastNAMSNewAmsterdam Pharma2.964 of 5 stars$27.05+1.3%$41.55+53.6%+68.3%$3.01B$45.56M-16.704HCMHUTCHMED2.4502 of 5 stars$16.66-2.2%$20.88+25.3%-23.4%$2.97B$630.20M0.001,811 Related Companies and Tools Related Companies Kymera Therapeutics Competitors Metsera Competitors MoonLake Immunotherapeutics Competitors Lantheus Competitors Telix Pharmaceuticals Competitors Crinetics Pharmaceuticals Competitors Amneal Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors NewAmsterdam Pharma Competitors HUTCHMED Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRAX) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIs This Warren’s Buffett’s #1 AI Investment?Did you know that Warren Buffett is investing in what Jeff Brown believes will be the next generation of artif...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Praxis Precision Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Praxis Precision Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
